Clinical Trial Detail

NCT ID NCT01576666
Title Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

gastroesophageal junction adenocarcinoma

stomach cancer

colorectal cancer

pancreatic adenocarcinoma

breast cancer

glioblastoma multiforme

Advanced Solid Tumor


Buparlisib + Sonidegib

Age Groups: adult

No variant requirements are available.